LDLijun Dou

Lijun Dou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lijun Dou has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Feixiong Cheng

    Cleveland Clinic, Cleveland, OH USA

    1 shared publication
  • Fenglong Yang

    Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University

    1 shared publication
  • Furong Tang

    Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China

    1 shared publication
  • Jielin Xu

    Cleveland Clinic, Cleveland, OH USA

    1 shared publication
  • Meiling Wang

    Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China

    1 shared publication
  • Shirong Lai

    Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China

    1 shared publication

Latest Publications

  • Open Access

    A deep learning‐based deconvolution framework identifies human brain cell‐type specific expression quantitative trait loci (eQTLs) and pathobiology in Alzheimer’s disease

    by Lijun Dou, Jielin Xu, Yuan Hou, Feixiong Cheng

    Background: Cell‐type specific expression quantitative trait loci (eQTLs) can help dissect cellular heterogeneity in the impact of genetic variation on gene expression for Alzheimer’s disease (AD) and AD‐related dementia (ADRD). However, due to the high cost and stringent sample collection criteria, it is challenging to obtain large single‐nuclei RNA sequencing (snRNA‐seq) data with sufficient cohort size to match genotyping data to systematically identify human brain‐specific eQTLs for AD/ADRD.Method: In this study, we presented a deep learning‐based deconvolution framework on large‐scale bulk RNA sequencing (RNA‐seq) data to infer cell‐type specific eQTLs in the human brains with AD/ADRD. Specifically, we first predicted the brain cell‐type specific gene expression for the harmonized bulk RNA dataset (n = 1,092) from Religious Orders Study and Memory and Aging Project (ROS/MAP). We then incorporated the inferred cell‐type specific gene expression with matched whole genome sequencing (WGS) data from ROS/MAP to identify the brain cell‐type specific eQTLs. These cell‐type specific eQTLs were further colocalized with AD genome‐wide association study (GWAS) findings to discover potential risk genes and druggable targets for AD.Result: We identified 44,504 genome‐wide significant cell‐type specific cis‐eQTLs (window size = 1Mb, p < 5 × 10‐8) from eight brain cell types, including excitatory neurons, inhibitory neurons, microglia, oligodendrocytes, oligodendrocyte precursor cells, astrocytes, and endothelium. Approximate 2,732 eQTLs in astrocytes and 7,628 in excitatory neurons are identical to the results from a large existing snRNA‐seq data, associated with the regulation of multiple genes (eGenes, e.g., ARL17B, LRRC37A2, ERAP2, PILRB, ZNF266). We illustrated that the GWAS variant rs199456 (AD GWAS: p = 2.57 × 10‐9) co‐localized with its regulatory effect on LRRC37A2, LRRC37A and ARL17B gene expression in excitatory neurons.Conclusion: In summary, this study presented comprehensive brain cell type‐specific eQTL analysis and identified potential eQTL‐regulated likely causal genes from AD GWAS findings using a deep learning‐based deconvolution framework. It offers an opportunity to efficiently discover the effect of GWAS loci on gene expression at cell type‐specific manners using genotyping data and matched bulk RNA‐seq data instead of costly snRNA‐seq data. Functional validation of candidate eQTLs and associated genes are warranted in the future.


  • Open Access

    Depression-associated gut microbes, metabolites and clinical trials

    by Meiling Wang, Zhaoqi Song, Shirong Lai, Furong Tang, Lijun Dou, Fenglong Yang

    Depression is one of the most prevalent mental disorders today. Over the past decade, there has been considerable attention given to the field of gut microbiota associated with depression. A substantial body of research indicates a bidirectional communication pathway between gut microbiota and the brain. In this review, we extensively detail the correlation between gut microbiota, including Lactobacillus acidophilus and Bifidobacterium longum, and metabolites such as short-chain fatty acids (SCFAs) and 5-hydroxytryptamine (5-HT) concerning depression. Furthermore, we delve into the potential health benefits of microbiome-targeted therapies, encompassing probiotics, prebiotics, and synbiotics, in alleviating depression. Lastly, we underscore the importance of employing a constraint-based modeling framework in the era of systems medicine to contextualize metabolomic measurements and integrate multi-omics data. This approach can offer valuable insights into the complex metabolic host-microbiota interactions, enabling personalized recommendations for potential biomarkers, novel drugs, and treatments for depression.